EGFR and non-small cell lung carcinoma: The results indicated that NSCLC patients treated with EGFR-TKI were divided into two subgroups based on the optimal cut-point, and high NRI was associated with poor OS of patients [hazard ratio (HR) = 1.60, 95% confidence interval (CI) 1.20–2.12, P = 0.001].